Why Travere Therapeutics Stock Got Trounced on Tuesday [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
10 stocks we like better than Travere Therapeutics › A fresh setback on the regulatory front was the development that put a damper on Travere Therapeutics (NASDAQ: TVTX) stock on Tuesday. Investors assertively sold out of Travere as a result, leaving the biotech 's shares with a nearly 15% loss on the day. Travere's leading drug candidate is Filspari, which targets a kidney disorder called focal segmental glomerulosclerosis (FSGS). The company announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline for evaluating the company's New Drug Application for the medication. The new target action date for the regulator to render a decision is April 13. That's exactly three months after the original self-imposed deadline of Jan. 13, Tuesday's date. Travere wrote in a press release that this follows its submission of responses requested by the FDA to, in the healthcare company's words, "further characterize the clinical benefit of Filspari." The st
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law FirmBusiness Wire
- Travere Therapeutics 2026 Outlook: Filspari Momentum, FSGS FDA Delay, And Market Potential [Seeking Alpha]Seeking Alpha
- Is Travere Therapeutics (TVTX) Pricing Reflect Long Term Value After Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLCGlobeNewswire
- TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA [Yahoo! Finance]Yahoo! Finance
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 1/13/26 - Form 8-K
- 1/12/26 - Form 8-K
- 1/8/26 - Form SCHEDULE
- TVTX's page on the SEC website